C
ryptosporidium is an intracellular protozoan para a asite and one of the most commonly reported enteric pathogens in both immunocompetent and immunocompromized hosts worldwide. It causes an infection resulting in diarrhea and biliary tract disa a ease 1 and is now recognized as a major cause of diarrhea in both immunosuppressed and immunocompetent hosts. The risk of severe and or prolonged disease is high in immunocompromized patients including solid organ transplantation recipients. It is more commonly seen in countries with increasing population and poor sanitary conditions. Prevalence is much higher in hua a man immunodeficiency virus (HIV)ainfected patients. 2 The treatment of cryptosporidiosis in immunosupa a pressed patients is still not clearly defined and response to proposed therapies is suboptimal.
Case
A 60ayearaold woman who received a livingarelated renal transplant 4 months earlier, presented with a 5a day history of colicky abdominal pain and watery diara a rhea 6a7 times per day. There was no vomiting, fever, or other constitutional symptoms. Her immunosupa a pressant regimen included tacrolimus 2 mg twice daily, prednisolone 10 mg once daily, and coatrimoxazole DS once daily. Other medications included mycostastin Suspension and omeprazole.
On examination she was fully oriented and afebrile with a blood pressure of 70/40 mm Hg. Her abdomen was soft and lax, with mild tenderness in the epigastria a um, left flank and sluggish bowl sounds. The remainder of her physical examination was unremarkable. She was started on intravenous fluid resuscitation with a normal saline bolus.
Lab results showed a normal complete blood count, urea 22 mmol/L, creatinine 351 umol/L, potassium 4.1 mEq/L, and sodium 132 mEq/L. Blood and stool cula a
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Khalil-ur-Rahman,* Abdullah Al-Amoudi,* Samar Badreddine,* Abdulraheem M Al-Shehri, † Hassan Kanaan, ‡ Saeed M.G Al-Ghamdi* tures were negative. Stool for Clostridium difficile toxin was negative. Colonoscopy with multiple biopsies from transverse, descending and rectosigmoidal colon were taken, and all showed the heavy presence of cryptospoa a ridium on PAS stain ( Figure 1 ). Esophageogastroduoa denoscopy was normal. Biopsies taken from the esopha a agus, stomach and duodenum showed no evidence of parasite, granuloma or inclusion bodies.
She was started on paromomycin 500 mg twice daily and loperamide. Her condition gradually improved, and her creatinine normalized with intravenous hydration. She was discharged after four days of admission on para a omomycin 500 mg orally three times dailty for 1 month in addition to her previous antiarejection regimen. On followaup visits, her diarrhea had completely stopped. One month after discontinuing paromomycin she had her regular bowel movement while her immunosupa a pressant was the same as before her hospitalization. Her serum creatinine was 73 µmol/L and her trough tacrolimus level was 6.6 µmol/L.
DisCussion
Cryptosporidiosis is a protozoal infection, which has been increasingly recognized as a cause of diarrheal illness in both immunocompetent and immunocoma a promised hosts. The risk of severe and prolonged disease is more in patients with cellular and humoral immune deficiencies including HIVainfected populaa a tion, organ transplant recipients, patients on immua a nosuppressant drugs, patients with IgA deficiency or hypogammaglobunemia. 3 The frequency of isolating Cryptosporidium from stool of renal transplant patients was significantly higher than that found in two control groups, one consisting of patients with endastage renal disease on hemodialysis and the other consisting of paa a tients with hypertension without renal abnormalities. 15 Infection is more common in countries with poor sania a tary conditions and increased crowding. Although more frequent in children less than 2 years of age, outbreaks occur worldwide in all age groups. 4, 5 Since early 1980s, massive outbreaks have been linked to municipal drinka a ing water supplied in different parts of the world, espea a cially Europe and North America. 6 Twentyafour species of Cryptosporidium have been identified. Cryptosporidium parvum is the only species responsible for clinical disease in humans, but it is not host specific, since it also infects other mammals. 7 Its transmission is via spreading from infected person or animal or fecally contaminated environmental source, such as food or water. 8 Pathogenesis is not well una a derstood, and no toxin has been identified. It causes secretary diarrhea, and the intracellular nature of the infection interferes with absorption of gut secretions. The organism can spread via intestinal lumen to involve biliary system where they can cause strictures and chola a angitis.
Diagnosis is usually established by identification of the organism in stool, duodenal aspirate or biopsy speca a imen. Since cryptosporidia spores are not detected by routine examination of the stool for ova and cyst, spea a cial stains are used such as Modified Acid Fast Stain. Fluorescent assays have been used to increase the sensia a tivity compared to light microscopy. 9, 10 Enzyme immua a noassay (EIA) kits are also available. Acid fast stain has a sensitivity of 94% and a specificity of 76% and EIA has a sensitivity and specificity of 100% compared to dia a rect immunofluorescence.
11 Serological detection using indirect fluorescentaantibody (IFA) assay or ELISA is also available. In our case, stool examination for parasite was negative but biopsies from the colon were positive.
There is no reliable therapy for cryptosporidiosis. Recovery usually depends on immune status of the host. Nonaspecific therapies are often given to immunodefia a cient patients including antiadiarrheal and supportive care with enteral or parenteral nutrition. A number of specific therapies have been tried. The largest experience is with paromomycin in acquired immune deficiency syndrome (AIDS) patients, where it was not found to be more effective than placebo. 12 In AIDS patients, the best treatment is improvement of the immune status with Highly Active Antiretroviral Therapy, which can help resolve cryptosporidium infection.
In renal transplant patients, no data are available on the best modality to treat this infection. Reduction of immunosuppressive therapy alone was reported to be associated with cure of Cryptosporidiumainduced sclea a rosing cholangitis. 13 Our patient responded well to paromomycin combined with an antiamotility agent. Establishing a definite role for paromomycin in treating cryptosporidium infections in renal transplant patients needs a welladesigned clinical trial. This is the first case report of the use of paromomycin in the treatment of Cryptosporidium in a renal transplant patient.
